Impaired adipogenic response to thiazolidinediones in mice expressing human apolipoproteinE4

FASEB Journal

Volumn 24, Issue 10, 2010, Pages 3809-3818

  Arbones Mainar, Jose M ^a   Johnson, Lance A ^a   Altenburg, Michael K ^a   Kim, Hyung Suk ^a   Maeda, Nobuyo ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adipogenesis; apoE; Fatty liver; Insulin resistance; NAFLD; Western type diet

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ADIPOGENESIS; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG EFFECT; ENZYME ACTIVATION; FATTY LIVER; GENE EXPRESSION; GLUCOSE TOLERANCE; IMPAIRED GLUCOSE TOLERANCE; LIPID BLOOD LEVEL; LIPID DIET; LIPID STORAGE; LIPID TRANSPORT; LIPOGENESIS; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; UPREGULATION; WEIGHT GAIN; ANIMAL; BODY WEIGHT; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM;

MUS;

ADIPOSE TISSUE; ANIMALS; APOLIPOPROTEIN E4; BODY WEIGHT; CELL DIFFERENTIATION; FATTY LIVER; HUMANS; MALE; MICE; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 77957837566     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.10-159517     Document Type: Article

References (37)

1. Mahley, R. W., Innerarity, T. L., Weisgraber, K. H., and Oh, S. Y. (1979) Altered metabolism (in vivo and in vitro) of plasma lipoproteins after selective chemical modification of lysine residues of the apoproteins. J. Clin. Invest. 64, 743-750
2. Knouff, C., Hinsdale, M. E., Mezdour, H., Altenburg, M. K., Watanabe, M., Quarfordt, S. H., Sullivan, P. M., and Maeda, N. (1999) Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J. Clin. Invest. 103, 1579-1586
3. Huang, Z. H., Gu, D., and Mazzone, T. (2009) Role of adipocyte-derived apoE in modulating adipocyte size, lipid metabolism, and gene expression in vivo. Am. J. Physiol. Endocrinol. Metab. 296, E1110-E1119
4. Pendse, A. A., Arbones-Mainar, J. M., Johnson, L. A., Altenburg, M. K., and Maeda, N. (2009) Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond. J. Lipid Res. 50, S178-S182
5. Davignon, J., Gregg, R., and Sing, C. (1988) Apolipoprotein E polymorphism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 8, 1-21
6. Bennet, A. M., Di Angelantonio, E., Ye, Z., Wensley, F., Dahlin, A., Ahlbom, A., Keavney, B., Collins, R., Wiman, B., de Faire, U., and Danesh, J. (2007) Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 298, 1300-1311 (Pubitemid 47443344)
7. Corder, E., Saunders, A., Strittmatter, W., Schmechel, D., Gaskell, P., Small, G., Roses, A., Haines, J., and Pericak-Vance, M. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923
8. Elosua, R., Demissie, S., Cupples, L. A., Meigs, J. B., Wilson, P. W. F., Schaefer, E. J., Corella, D., and Ordovas, J. M. (2003) Obesity modulates the association among APOE genotype, insulin, and glucose in men. Obes. Res. 11, 1502-1508
9. Sima, A., Iordan, A., and Stancu, C. (2007) Apolipoprotein E polymorphism: a risk factor for metabolic syndrome. Clin. Chem. Lab. Med. 45, 1149-1153 (Pubitemid 47396270)
10. Arbones-Mainar, J. M., Johnson, L. A., Altenburg, M. K., and Maeda, N. (2008) Differential modulation of diet-induced obesity and adipocyte functionality by human apolipoprotein E3 and E4 in mice. Int. J. Obes. 32, 1595-1605
11. Yki-Jarvinen, H. (2004) Thiazolidinediones. N. Engl. J. Med. 351, 1106-1118
12. Arbones-Mainar, J. M., Navarro, M. A., Acin, S., Guzman, M. A., Arnal, C., Surra, J. C., Carnicer, R., Roche, H. M., and Osada, J. (2006) Trans-10, cis-12-and cis-9, trans-11-conjugated linoleic acid isomers selectively modify HDL-apolipoprotein composition in apolipoprotein E knockout mice. J. Nutr. 136, 353-359 (Pubitemid 43228286)
13. Altenburg, M., Arbones-Mainar, J., Johnson, L., Wilder, J., and Maeda, N. (2008) Human LDL receptor enhances sequestration of ApoE4 and VLDL remnants on the surface of hepatocytes but not their internalization in mice. Arterioscler. Thromb. Vasc. Biol. 28, 1104-1110
14. Johnson, L. A., Altenburg, M. K., Walzem, R. L., Scanga, L. T., and Maeda, N. (2008) Absence of hyperlipidemia in LDL receptor-deficient mice having apolipoprotein B100 without the putative receptor-binding sequences. Arterioscler. Thromb. Vasc. Biol. 28, 1745-1752
15. Conner, D. (2001) Mouse embryo fibroblast (MEF) feeder cell preparation. Curr. Protoc. Mol. Biol. 23, 23.2.1-23.2.7
16. Huang, Z. H., Reardon, C. A., and Mazzone, T. (2006) Endogenous ApoE expression modulates adipocyte triglyceride content and turnover. Diabetes 55, 3394-3402
17. Bazin, R., and Ferre, P. (2001) Assays of lipogenic enzymes. In Methods in Molecular Biology-Adipose Tissue Protocols, Vol. 155 (Ailhaud, G., ed), pp. 121-127, Humana Press, Towota, NJ, USA
18. Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S., and Cooper, G. J. (2003) The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest. 112, 91-100
19. Pagano, C., Soardo, G., Esposito, W., Fallo, F., Basan, L., Donnini, D., Federspil, G., Sechi, L. A., and Vettor, R. (2005) Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur. J. Endocrinol. 152, 113-118
20. Ye, J.-M., Dzamko, N., Cleasby, M. E., Hegarty, B. D., Furler, S. M., Cooney, G. J., and Kraegen, E. W. (2004) Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia 47, 1306-1313
21. Im, S., Kang, S., Kim, S., Kim, H., Kim, J., Kim, K., and Ahn, Y. (2005) Glucose-stimulated upregulation of GLUT2 gene is mediated by sterol response element-binding protein-1c in the hepatocytes. Diabetes 54, 1684-1689 (Pubitemid 40770758)
22. Ranganathan, G., Unal, R., Pokrovskaya, I., Yao-Borengasser, A., Phanavanh, B., Lecka-Czernik, B., Rasouli, N., and Kern, P. A. (2006) The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment. J. Lipid Res. 47, 2444-2450
23. Bogacka, I., Xie, H., Bray, G. A., and Smith, S. R. (2004) The effect of pioglitazone on peroxisome proliferator-activated receptor-γ target genes related to lipid storage in vivo. Diabetes Care 27, 1660-1667
24. Horton, J. D., Goldstein, J. L., and Brown, M. S. (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125-1131
25. Chao, L., Marcus-Samuels, B., Mason, M. M., Moitra, J., Vinson, C., Arioglu, E., Gavrilova, O., and Reitman, M. L. (2000) Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J. Clin. Invest. 106, 1221-1228
26. Shimomura, I., Bashmakov, Y., and Horton, J. D. (1999) Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J. Biol. Chem. 274, 30028-30032
27. Gavrilova, O., Haluzik, M., Matsusue, K., Cutson, J. J., Johnson, L., Dietz, K. R., Nicol, C. J., Vinson, C., Gonzalez, F. J., and Reitman, M. L. (2003) Liver peroxisome proliferator-activated receptor {gamma} contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 278, 34268-34276
28. Westerbacka, J., Kolak, M., Kiviluoto, T., Arkkila, P., Siren, J., Hamsten, A., Fisher, R. M., and Yki-Jarvinen, H. (2007) Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes 56, 2759-2765
29. García-Ruiz, I., Rodríguez-Juan, C., Díaz- Sanjuán, T., Ángel Martínez, M., Muñoz-Yagüe, T., and Solís-Herruzo, J. (2007) Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice. Hepatology 46, 414-423
30. Yue, L., and Mazzone, T. (2009) Peroxisome proliferator-activated receptor γ stimulation of adipocyte ApoE gene transcription mediated by the liver receptor X pathway. J. Biol. Chem. 284, 10453-10461
31. Yue, L., Rasouli, N., Ranganathan, G., Kern, P. A., and Mazzone, T. (2004) Divergent effects of peroxisome proliferator-activated receptor {gamma} agonists and tumor necrosis factor α on adipocyte ApoE expression. J. Biol. Chem. 279, 47626-47632 (Pubitemid 39540908)
32. Malloy, S. I., Altenburg, M. K., Knouff, C., Lanningham-Foster, L., Parks, J. S., and Maeda, N. (2004) Harmful effects of increased LDLR expression in mice with human APOE*4 but not APOE*3. Arterioscler. Thromb. Vasc. Biol. 24, 91-97
33. Cardona, F., Morcillo, S., Gonzalo-Marin, M., Garrido-Sanchez, L., Macias-Gonzalez, M., and Tinahones, F. J. (2006) Pro12Ala sequence variant of the PPARG gene is associated with postprandial hypertriglyceridemia in non-E3/E3 patients with the metabolic syndrome. Clin. Chem. 52, 1920-1925
34. Peng, D. Q., Zhao, S. P., Nie, S., and Li, J. (2003) Gene-gene interaction of PPARγ and ApoE affects coronary heart disease risk. Int. J. Cardiol. 92, 257-263
35. Smith, G. S., de Leon, M. J., George, A. E., Kluger, A., Volkow, N. D., McRae, T., Golomb, J., Ferris, S. H., Reisberg, B., Ciaravino, J., and La Regina, M. E. (1992) Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease: pathophysiologic implications. Arch. Neurol. 49, 1142-1150
36. Small, G. W., Mazziotta, J. C., Collins, M. T., Baxter, L. R., Phelps, M. E., Mandelkern, M. A., Kaplan, A., La Rue, A., Adamson, C. F., Chang, L., Guze, B. H., Corder, E. H., Saunders, A. M., Haines, J. L., Pericak-Vance, M. A., and Roses, A. D. (1995) Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273, 942-947
37. Risner, M. E., Saunders, A. M., Altman, J. F., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., and Roses, A. D. (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 6, 246-254.